Nearly one-third of patients with rheumatoid arthritis (RA) do not respond to Methotrexate (MTX), the first-line therapy in RA. CD39, an ectonucleotidase highly expressed on regulatory T cells (Tregs), is responsible for production of adenosine, an important anti-inflammatory mediator of MTX action. Higher expression of CD39 on Tregs improves their suppressive capacity. Therefore, we aimed to study the role of CD39
Patients with active RA who were naive to disease-modifying anti-rheumatic drugs were enrolled. Frequencies of CD39
After 4 months of MTX monotherapy, 54 patients were classified as responders and 16 as non-responders. The baseline CD39
Higher frequencies of CD39